Infographic: Consensus Recommendations on Biosimilars in Rheumatology

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory diseases.

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."

The biosimilar industry faces awareness challenges among health care professionals (HCPs), which must be addressed to increase cost savings and patient access to treatments.

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events.

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to affordable biosimilars.